Background Immune checkpoint inhibitors can stimulate immune responses to tumour
neoantigens. Tumour mutational burden (TMB), a surrogate for neoantigen load, is …

The advent of immunotherapy, especially immune checkpoint inhibitors (ICIs), has
revolutionized antitumor therapy. Programmed cell death receptor 1 (PD-1) and …

Immunotherapy is currently approved for a subset of patients diagnosed with advanced triple
negative breast cancer (TNBC), based on the phase III randomized controlled trial …

Background One of the front treatment regimens used for metastatic triple-negative breast
cancer (mTNBC) is treatment with programmed death-1 (PD-1) or programmed death ligand …

Triple-negative breast cancer (TNBC) is considered one of the highest-risk subtypes of
breast cancer and has dismal prognosis. Local recurrence rate after standard therapy in the …

Chemotherapy is the mainstay of treatment for triple-negative breast cancer (TNBC), but
taxane resistance remains problematic. TNBC tumors often demonstrate upregulation of the …

Objective: This study evaluated the cost–effectiveness of pembrolizumab/chemotherapy
combinations for previously untreated metastatic triple-negative breast cancer patients in the …

Abstract 1 in 8 women will be affected by breast cancer, which is the most diagnosed
malignancy among women. Although breast cancer was regarded as “immunologically …

Objective: To determine efficacy and safety of pembrolizumab, a humanized IgG4
monoclonal antibody against programmed death receptor 1 (PD-1), in pts with mTNBC …

TPS597 Background: Early stage triple negative breast cancer (TNBC) is associated with a
high risk of distant relapse. Because TNBC does not currently have specific targeted agents …